5-methyl-3-(trifluoromethyl)pyrazin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-methyl-3-(trifluoromethyl)pyrazin-2-amine
• 英文别名: 2-Pyrazinamine, 5-methyl-3-(trifluoromethyl)-
• 化学式: C₆H₆F₃N₃
• 分子量: 177.129
• InChiKey: ZUUGOMIJZWEGQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-methyl-3-(trifluoromethyl)pyrazin-2-amine 在 copper(l) iodide 、 potassium iodide 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 生成 2-iodo-5-methyl-3-(trifluoromethyl)pyrazine
  参考文献：
  名称：

  [EN] REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS
  [FR] AGONISTES REV-ERB POUR DES TROUBLES INFLAMMATOIRES À MÉDIATION PAR TH17

  摘要：

  The present disclosure provides compounds and their pharmaceutical compositions as selective agonists of REV-ERBα. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

  公开号：

  WO2023122093A1
• 作为产物：
  描述：

  2-氨基-三氟甲基吡嗪 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 16.0h， 生成 5-methyl-3-(trifluoromethyl)pyrazin-2-amine
  参考文献：
  名称：

  [EN] REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS
  [FR] AGONISTES REV-ERB POUR DES TROUBLES INFLAMMATOIRES À MÉDIATION PAR TH17

  摘要：

  The present disclosure provides compounds and their pharmaceutical compositions as selective agonists of REV-ERBα. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

  公开号：

  WO2023122093A1

文献信息

• Compounds for treating spinal muscular atrophy
  申请人：PTC Therapeutics Inc.

  公开号：US09617268B2

  公开（公告）日：2017-04-11

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物和使用方法。在一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN2基因转录的mRNA中SMN2的外显子7的包含。在另一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN1基因转录的mRNA中SMN1的外显子7的包含。在另一个实施例中，本文提供了一种形式的化合物，可用于调节从SMN1和SMN2基因分别转录的mRNA中SMN1和SMN2的外显子7的包含。
• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics Inc.

  公开号：US20150119380A1

  公开（公告）日：2015-04-30

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物及与其一起使用的用途。在一个具体实施例中，本文提供了一种可以用来调节SMN2基因转录的mRNA中包含外显子7的形式化合物。在另一个具体实施例中，本文提供了一种可以用来调节SMN1基因转录的mRNA中包含外显子7的形式化合物。在另一个实施例中，本文提供了一种可以用来调节SMN1和SMN2基因转录的mRNA中包含外显子7的形式化合物。
• COMPOUNDS FOR USE IN ANTHELMINTHIC TREATMENT
  申请人：Bayer Animal Health GMBH

  公开号：US20170217931A1

  公开（公告）日：2017-08-03

  Disclosed are compounds of formula (I) which possess anthelminthic properties wherein the structural elements have the meaning as indicated in the description. Further disclosed are such compounds for the control, treatment and/or prevention of infections with helminths in animals and humans.
• HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：US20220144801A1

  公开（公告）日：2022-05-12

  The present invention relates to herbicidally active pyridyl-/pyrimidyl-pyrazine derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.
• US9617268B2
  申请人：——

  公开号：US9617268B2

  公开（公告）日：2017-04-11